Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

The FDA approval process for Brilacidin has been p

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
(Total Views: 650)
Posted On: 08/05/2021 9:59:54 AM
Posted By: SickWatts
The FDA approval process for Brilacidin has been painfully slow. B, with an SI of 426 is now in the "queue" for Delta testing while people needlessly suffer and die.

Yet the FDA quickly gave EUA to Big Pharm. Raises serious and justifiable questions about the approval process.

See slide 16--October 22, 2020.

https://www.fda.gov/media/143557/download

And the only EUA therapeutic approved by the FDA is Veklury (Remdesivir), earning Gilead $2.7 billion in 2020 and projected $3 billion in 2021.

From the Remdesivir Fact Sheet for parents and caregivers:

What are the important possible side effects of VEKLURY?
Possible side effects of VEKLURY are:
• Allergic reactions. Allergic reactions can happen during and after infusion with VEKLURY. Tell your healthcare
provider right away if your child gets any of the following signs and symptoms of allergic reactions: changes to
heart rate, fever, shortness of breath, wheezing, swelling of the lips, face, or throat, rash, nausea, sweating, or
shivering.
• Increases in levels of liver enzymes. Increases in liver enzymes are common in people who have received
VEKLURY and may be a sign of liver injury. Your healthcare provider will do blood tests to check your child’s
liver enzymes before receiving VEKLURY and as needed while receiving VEKLURY. Your healthcare provider
may stop treatment with VEKLURY if your child develops new or worsening liver problems.
The most common side effect of VEKLURY is nausea.
These are not all the possible side effects of VEKLURY. VEKLURY is still being studied so it is possible that all of
the risks are not known at this time.

https://www.fda.gov/media/137565/download


(6)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us